Birchview Capital’s Acceleron Pharma XLRN Stock Holding History

Birchview Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,672	Closed	-$1.84M	–	70
2021 Q3	$1.84M	Sell	10,672 -8,000	-43%	-$1.05M	1.25%	13
2021 Q2	$2.34M	Hold	18,672	–	–	1.4%	13
2021 Q1	$2.53M	Hold	18,672	–	–	1.5%	11
2020 Q4	$2.39M	Hold	18,672	–	–	1.38%	15
2020 Q3	$2.1M	Hold	18,672	–	–	1.4%	11
2020 Q2	$1.78M	Hold	18,672	–	–	1.08%	16
2020 Q1	$1.68M	Hold	18,672	–	–	1.49%	11
2019 Q4	$990K	Hold	18,672	–	–	0.72%	23
2019 Q3	$738K	Hold	18,672	–	–	0.49%	20
2019 Q2	$767K	Hold	18,672	–	–	0.47%	22
2019 Q1	$870K	Hold	18,672	–	–	0.55%	21
2018 Q4	$813K	Buy	18,672 +6,672	+56%	+$333K	0.77%	17
2018 Q3	$687K	Hold	12,000	–	–	0.44%	25
2018 Q2	$582K	Sell	12,000 -13,000	-52%	-$474K	0.4%	26
2018 Q1	$978K	Hold	25,000	–	–	0.64%	14
2017 Q4	$1.06M	Hold	25,000	–	–	0.62%	13
2017 Q3	$933K	Buy	25,000 +10,000	+67%	+$347K	0.48%	15
2017 Q2	$456K	Buy	+15,000	New	+$435K	0.24%	27

Birchview Capital's XLRN Position: Q4 2021 in Review

Birchview Capital sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 10,672 shares — an estimated $1.84M sold.

Birchview Capital first reported a position in XLRN in Q2 2017 and held it in 18 quarters. The position peaked at $2.53M in Q1 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Birchview Capital reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Birchview Capital sold 10,672 Acceleron Pharma shares in Q4 2021, an estimated $1.84M.
Birchview Capital first reported a position in Acceleron Pharma in Q2 2017 and held it in 18 quarters.
Birchview Capital's Acceleron Pharma position peaked at $2.53M in Q1 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Birchview Capital's 13F filing for Q4 2021, filed 14 Feb 2022.